Summary:

- Gilead Sciences is developing a once-yearly injectable HIV prevention drug called lenacapavir, which could help improve adherence to PrEP (pre-exposure prophylaxis) regimens.
- Lenacapavir works by inhibiting HIV's ability to integrate its genetic material into human cells, providing long-lasting protection against infection.
- Clinical trials have shown lenacapavir to be safe and effective, and Gilead plans to submit it for regulatory approval in 2023, potentially offering a new option for people at high risk of HIV infection.